Physician profile
Robert B Barger
NPI 1699754887
$2,196.93
in general payments reported to CMS, 2019-2025
32 companies · $459 in 2025
The $459 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $190 · 2021: $411 · 2022: $400 · 2023: $301 · 2024: $270 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.33 |
| Education | $117.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.85 | 2020-2023 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $350.06 | 2021-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $156.16 | 2021-2024 | |
| Daiichi Sankyo INC. | $132.80 | 2020-2023 | Injectafer |
| Mayne Pharma Commercial LLC | $126.96 | 2021-2025 | |
| Therapeuticsmd, INC. | $98.70 | 2019-2021 | |
| Biogen, INC. | $90.51 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $82.65 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Allergan, INC. | $62.12 | 2019-2020 | |
| Exeltis, USA INC. | $60.74 | 2022-2024 | Slynd |
| Pfizer INC. | $59.18 | 2022-2025 | |
| Optumhealth Care Solutions, LLC | $52.75 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Millicent US INC | $45.00 | 2025 | |
| Dexcom, INC. | $42.91 | 2025 | Dexcom G6 Transmitter |
| Hydrofera LLC | $36.37 | 2025 | Sorbact Other |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $36.32 | 2019-2021 | |
| Heron Therapeutics, INC. | $30.56 | 2024-2025 | Zynrelef |
| Organon LLC | $28.80 | 2023-2024 | Nexplanon |
| Medtronic, INC. | $25.49 | 2024 | Protack |
| Merck Sharp & Dohme LLC | $25.40 | 2019-2021 | |
| Glaxosmithkline, LLC. | $23.58 | 2024 | Pediarix, Bexsero, Menveo |
| Lilly USA, LLC | $22.53 | 2025 | Zepbound |
| Avion Pharmaceuticals | $19.08 | 2022 | |
| Smith+Nephew, INC. | $18.81 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.12 | 2019 | |
| Amgen INC. | $17.48 | 2019 | |
| Olympus America INC. | $17.42 | 2022 | |
| Evofem Biosciences, INC. | $14.01 | 2020 | |
| Axsome Therapeutics, INC. | $13.76 | 2025 | Auvelity |
| Myovant Sciences INC. | $13.36 | 2022 | |
| Davol INC. | $11.92 | 2021 | |
| Meditrina | $9.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.